190 related articles for article (PubMed ID: 36451444)
21. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
22. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
23. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
24. Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.
Chen M; Liu X; Du J; Wang XJ; Xia L
Oncotarget; 2017 Jan; 8(1):133-144. PubMed ID: 27863400
[TBL] [Abstract][Full Text] [Related]
25. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
26. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
Gong L; Liu Q; Jia M; Sun X
Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
[TBL] [Abstract][Full Text] [Related]
27. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
29. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
Liu B; Liu Y; Zou J; Zou M; Cheng Z
Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
[TBL] [Abstract][Full Text] [Related]
30. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral Microbiota-Host Interactions Shape the Variability of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma in Recurrence and Metastasis.
Zhou X; Ji L; Ma Y; Tian G; Lv K; Yang J
Microbiol Spectr; 2023 Jun; 11(3):e0373822. PubMed ID: 37074188
[TBL] [Abstract][Full Text] [Related]
33. MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.
Petkova V; Marinova D; Kyurkchiyan S; Stancheva G; Mekov E; Kachakova-Yordanova D; Slavova Y; Kostadinov D; Mitev V; Kaneva R
Medicine (Baltimore); 2022 Aug; 101(33):e30027. PubMed ID: 35984198
[TBL] [Abstract][Full Text] [Related]
34. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
35. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
36. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
[TBL] [Abstract][Full Text] [Related]
37. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
Cao B; Wang P; Gu L; Liu J
Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
[TBL] [Abstract][Full Text] [Related]
38. In-depth analysis of immune cell landscapes reveals differences between lung adenocarcinoma and lung squamous cell carcinoma.
Wang X; Zheng K; Hao Z
Front Oncol; 2024; 14():1338634. PubMed ID: 38333684
[TBL] [Abstract][Full Text] [Related]
39. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC).
Zhang L; Chen J; Cheng T; Yang H; Li H; Pan C
J Cancer; 2020; 11(17):4965-4979. PubMed ID: 32742444
[TBL] [Abstract][Full Text] [Related]
40. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
